Quay Pharmaceuticals
Quay House
28 Parkway, Deeside Industrial Park
Desside, Flintshire
CH5 2NS
United Kingdom
Tel: +151 203 9817
Fax: +1244 281 283
Web: www.quaypharma.com
Quay Pharmaceuticals are experienced in providing a
comprehensive out-sourcing service for formulation and analytical development
with subsequent clinical trials manufacturing for pharmaceutical and
biotechnology companies world-wide.
Working as a dedicated, pro-active part of your team we apply strong project
management and technical expertise to take products quickly and cost effectively
from late stage pre clinical through to the end of phase II clinical trials.
Quay Pharma has vast expertise in dosage form design and development and with
Professor Mike Rubinstein (CEO) and Professor John Collett (CSO), Quay Pharma
has built a reputation for specialising in the formulation of NCE’s that exhibit
poor solubility and bio-availability. Pioneering the use of lipophilic systems
has resulted in many Quay Pharma clients successfully licensing products on to
large, global pharmaceutical companies.
Quay Pharma holds a Manufacturing Authorisation from the MHRA for the
manufacture and testing of investigational medicinal products (IMP’s), as
specified by the EU Clinical Trials Directive (2001/20/EC) and also possesses a
“Specials” licence.Group Sector
- Preformulation
- Formulation development
- Analytical method development
- Clinical trials manufacture through to end of
Phase II
- Full QC services
- QP certification
Geographical Area
Global and through our agent, InterPharm Express in
Japan.
Contact
Maireadh A. Pedersen Head of Business development
| 
